HER-2 Positive Breast Cancer Completed Phase 2 Trials for Ganetespib (DB12047)

IndicationStatusPhase
DBCOND0042425 (HER-2 Positive Breast Cancer)Completed2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT01677455An Open-Label Multicenter Phase 2 Window of Opportunity Study Evaluating Ganetespib in Women With Breast CancerTreatment